Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04846868




Registration number
NCT04846868
Ethics application status
Date submitted
13/04/2021
Date registered
15/04/2021
Date last updated
26/06/2024

Titles & IDs
Public title
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
Scientific title
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)
Secondary ID [1] 0 0
2020-003760-11
Secondary ID [2] 0 0
1346-0011
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Schizophrenia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Iclepertin
Treatment: Drugs - Placebo

Experimental: Iclepertin -

Placebo comparator: Placebo -


Treatment: Drugs: Iclepertin
Iclepertin

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) after 26 weeks of treatment
Timepoint [1] 0 0
at baseline and at week 26
Secondary outcome [1] 0 0
Change from baseline in the Schizophrenia Cognition Rating Scale (SCoRS) interviewer total score after 26 weeks of treatment
Timepoint [1] 0 0
at baseline and at week 26
Secondary outcome [2] 0 0
Change from baseline to Week 26 in the adjusted total time T-score in the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
Timepoint [2] 0 0
at baseline and at week 26
Secondary outcome [3] 0 0
Change from baseline to Week 26 in the T-score of the number of correct responses on Tower of London (ToL) test
Timepoint [3] 0 0
at baseline and at week 26
Secondary outcome [4] 0 0
Change from screening visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) total score
Timepoint [4] 0 0
up to 24 weeks

Eligibility
Key inclusion criteria
Inclusion criteria

1. Patients must be capable of providing signed and dated written informed consent by date of Visit 1 in accordance with ICH Harmonized Tripartite Guideline for Good Clinical Practice (ICH-GCP) and the local legislation prior to the admission to the trial.
2. Male or female patients who are 18-50 years (inclusive) of age at time of consent.
3. Diagnosis of schizophrenia utilizing Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) with the following clinical features:

* Outpatient, clinically stable and in the residual (non-acute) phase of their illness.
* No hospitalization or increase in level of psychiatric care due to worsening of schizophrenia within 12 weeks prior to randomization.
* Positive and Negative Syndrome Scale (PANSS) score: items P1, P3-P6 = 5 and item P2 and P7 = 4 at Visit 1, and confirmed at Visit 2.
4. Patients should have functional impairment in day-to-day activities such as difficulties following conversation or expressing themselves, difficulties to stay focused, difficulties to remember instructions, what to say or how to get to places, per investigator judgement.
5. Patients maintained on current antipsychotic treatment (minimum 1 and maximum 2 antipsychotics, but clozapine is not allowed) for at least 12 weeks and on current dose for at least 35 days prior to randomization.

-- For patients on two antipsychotics, at least one antipsychotic must be within the approved label dose range. The second antipsychotic must not exceed the maximum daily dose per local label.

Note: If the total dose is stable, different dosage forms of the same antipsychotic treatment will be considered as one antipsychotic.
6. Patients with any other concomitant psychoactive medications (except for anticholinergics) need to be maintained on same drug for at least 12 weeks and on current dose/ regimen for at least 35 days prior to randomization.

* Maximum daily benzodiazepine load of up to 1 mg lorazepam-equivalent.
* For any other psychoactive medications, doses cannot exceed the maximum daily dose per local label.
7. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3 (R2)) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the protocol. Such methods should be used throughout the trial, and for a period of at least 35 days after last trial drug intake, and the patient must agree to periodic pregnancy testing during participation in the trial.
8. Have a study partner, defined as any person either private or professional who knows the patient well, has been capable of interacting with the patient on regular basis, and preferably consistent throughout the study.

* The study partner must interact with the subject a minimum 1 hour per week and, preferably, at least 2 times a week. At least one interaction per week should be in person.
* The study partner must have educational achievement of minimum 8th grade.
* Professional study partners (e.g. study nurse, social worker etc.) are allowed if not involved in administration of any of the protocol assessments.

Further inclusion criteria apply.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria

1. Participant with current DSM-5 diagnosis other than Schizophrenia, including but not limited to bipolar, schizoaffective, major depressive disorder etc. Mini International Neuropsychiatric Interview (M.I.N.I.) for Psychotic disorders should be used for guidance.
2. Cognitive impairment due to developmental, neurological (e.g., epilepsy, stroke) or other disorders including head trauma, or patients with dementia or epilepsy.
3. Severe movement disorders

* Leading to cognitive impairment (e.g. Parkinson dementia), or
* Interfering with the efficacy assessments, or
* Due to antipsychotic treatment that cannot be controlled with low dose anticholinergic treatment (equal to maximum 1 mg benztropine twice daily).
4. Any suicidal behavior in the past 1-year prior to screening and during the screening period.
5. Suicidal ideation of type 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) (i.e. active suicidal thought with plan and intent) in the past 3 months prior to screening and up to and including Visit 2.

-- Patients with Suicidal Ideation type 4 in the C-SSRS (i.e. active suicidal thought with intent but without specific plan), within 3 months prior to screening and up to and including Visit 2, can be randomized in the study, if assessed and documented by a licensed mental health professional that there is no immediate risk of suicide.
6. History of moderate or severe substance use disorder (other than caffeine and nicotine), as defined in DSM-5 within the last 12 months prior to informed consent.
7. Positive urine drug screen at Visit 1 based on central lab test.
8. Patients who were treated with any of the following within 6 months prior to randomization:

* Clozapine
* Stimulants (e.g. methylphenidate, dextroamphetamine, modafinil)
* Ketamine or esketamine
* Electroconvulsive therapy (ECT) or Modified ECT Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
11/10/2024
Actual
Sample size
Target
Accrual to date
Final
620
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Alfred Psychiatry Research Centre - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Oregon
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
Brazil
State/province [10] 0 0
Belo Horizonte,Minas Gerais
Country [11] 0 0
Brazil
State/province [11] 0 0
Belo Horizonte
Country [12] 0 0
Brazil
State/province [12] 0 0
Criciuma
Country [13] 0 0
Brazil
State/province [13] 0 0
Curitiba
Country [14] 0 0
Brazil
State/province [14] 0 0
Goiania
Country [15] 0 0
Brazil
State/province [15] 0 0
Sao Jose do Rio Preto
Country [16] 0 0
Brazil
State/province [16] 0 0
Sao Paulo
Country [17] 0 0
Canada
State/province [17] 0 0
Alberta
Country [18] 0 0
Canada
State/province [18] 0 0
British Columbia
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
China
State/province [20] 0 0
Baoding
Country [21] 0 0
China
State/province [21] 0 0
Beijing
Country [22] 0 0
China
State/province [22] 0 0
Changsha
Country [23] 0 0
China
State/province [23] 0 0
Guangzhou
Country [24] 0 0
China
State/province [24] 0 0
Guiyang
Country [25] 0 0
China
State/province [25] 0 0
Jining
Country [26] 0 0
China
State/province [26] 0 0
Kunming
Country [27] 0 0
China
State/province [27] 0 0
Ningbo
Country [28] 0 0
China
State/province [28] 0 0
Shanghai
Country [29] 0 0
China
State/province [29] 0 0
Wuxi
Country [30] 0 0
China
State/province [30] 0 0
Xinxiang
Country [31] 0 0
Colombia
State/province [31] 0 0
Barranquilla
Country [32] 0 0
Colombia
State/province [32] 0 0
Bello
Country [33] 0 0
Colombia
State/province [33] 0 0
Bogota
Country [34] 0 0
Colombia
State/province [34] 0 0
Bogotá
Country [35] 0 0
Colombia
State/province [35] 0 0
Pereira
Country [36] 0 0
Germany
State/province [36] 0 0
Bad Homburg
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Mannheim
Country [39] 0 0
Germany
State/province [39] 0 0
Westerstede
Country [40] 0 0
Greece
State/province [40] 0 0
Athens
Country [41] 0 0
Greece
State/province [41] 0 0
Chaidari
Country [42] 0 0
Greece
State/province [42] 0 0
Haidari
Country [43] 0 0
Greece
State/province [43] 0 0
Heraclion
Country [44] 0 0
Greece
State/province [44] 0 0
Nea Kifisia
Country [45] 0 0
Greece
State/province [45] 0 0
Thessaloniki
Country [46] 0 0
Italy
State/province [46] 0 0
Brescia
Country [47] 0 0
Italy
State/province [47] 0 0
Milano
Country [48] 0 0
Italy
State/province [48] 0 0
Orbassano (to)
Country [49] 0 0
Italy
State/province [49] 0 0
Siena
Country [50] 0 0
Japan
State/province [50] 0 0
Aichi, Konan
Country [51] 0 0
Japan
State/province [51] 0 0
Chiba, Ichikawa
Country [52] 0 0
Japan
State/province [52] 0 0
Fukuoka, Fukuoka
Country [53] 0 0
Japan
State/province [53] 0 0
Fukuoka, Omuta
Country [54] 0 0
Japan
State/province [54] 0 0
Hokkaido, Obihiro
Country [55] 0 0
Japan
State/province [55] 0 0
Hokkaido, Sapporo
Country [56] 0 0
Japan
State/province [56] 0 0
Kanagawa, Kawasaki
Country [57] 0 0
Japan
State/province [57] 0 0
Kanagawa, Sagamihara
Country [58] 0 0
Japan
State/province [58] 0 0
Kanagawa, Yokohama
Country [59] 0 0
Japan
State/province [59] 0 0
Kochi, Kochi
Country [60] 0 0
Japan
State/province [60] 0 0
Kyoto, Maizuru
Country [61] 0 0
Japan
State/province [61] 0 0
Miyagi, Sendai
Country [62] 0 0
Japan
State/province [62] 0 0
Nagano, Matsumoto
Country [63] 0 0
Japan
State/province [63] 0 0
Niigata, Niigata
Country [64] 0 0
Japan
State/province [64] 0 0
Saga, Kanzaki-gun
Country [65] 0 0
Japan
State/province [65] 0 0
Saitama, Iruma-gun
Country [66] 0 0
Japan
State/province [66] 0 0
Saitama, Kumagaya
Country [67] 0 0
Japan
State/province [67] 0 0
Saitama, Saitama
Country [68] 0 0
Japan
State/province [68] 0 0
Tochigi, Shimotsuga-gun
Country [69] 0 0
Japan
State/province [69] 0 0
Tokushima, Tokushima
Country [70] 0 0
Japan
State/province [70] 0 0
Tokyo, Kodaira
Country [71] 0 0
Japan
State/province [71] 0 0
Tokyo, Machida
Country [72] 0 0
Japan
State/province [72] 0 0
Tokyo, Setagaya
Country [73] 0 0
Japan
State/province [73] 0 0
Tokyo, Shinjuku-ku
Country [74] 0 0
Japan
State/province [74] 0 0
Tokyo, Toshima-ku
Country [75] 0 0
Japan
State/province [75] 0 0
Yamaguchi, Ube
Country [76] 0 0
Japan
State/province [76] 0 0
Yamanashi, Chuo
Country [77] 0 0
Mexico
State/province [77] 0 0
Cdmx
Country [78] 0 0
Mexico
State/province [78] 0 0
Ciudad de Mexico
Country [79] 0 0
Mexico
State/province [79] 0 0
Guadalajara
Country [80] 0 0
Mexico
State/province [80] 0 0
Merida
Country [81] 0 0
Mexico
State/province [81] 0 0
Monterrey
Country [82] 0 0
New Zealand
State/province [82] 0 0
Takpuna Auckland
Country [83] 0 0
Norway
State/province [83] 0 0
Moss
Country [84] 0 0
Norway
State/province [84] 0 0
Oslo
Country [85] 0 0
Philippines
State/province [85] 0 0
Iloilo City
Country [86] 0 0
Philippines
State/province [86] 0 0
Makati City
Country [87] 0 0
Philippines
State/province [87] 0 0
Manila, Philippines
Country [88] 0 0
Poland
State/province [88] 0 0
Bialystok
Country [89] 0 0
Poland
State/province [89] 0 0
Lodz
Country [90] 0 0
Poland
State/province [90] 0 0
Poznan
Country [91] 0 0
Poland
State/province [91] 0 0
Warsaw
Country [92] 0 0
Poland
State/province [92] 0 0
Zabrze
Country [93] 0 0
Sweden
State/province [93] 0 0
Helsingborg
Country [94] 0 0
Sweden
State/province [94] 0 0
Uppsala
Country [95] 0 0
Turkey
State/province [95] 0 0
Ankara
Country [96] 0 0
Turkey
State/province [96] 0 0
Istanbul
Country [97] 0 0
Turkey
State/province [97] 0 0
Izmir
Country [98] 0 0
Turkey
State/province [98] 0 0
Manisa

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called Iclepertin improves learning and memory in people with schizophrenia.

Participants are put into two groups randomly, which means by chance. One group takes Iclepertin tablets and the other group takes placebo tablets. Placebo tablets look like Iclepertin tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia.

During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups.

Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.
Trial website
https://clinicaltrials.gov/study/NCT04846868
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries